uniQure stock faces 2027 FDA decision after Q3 update

uniQure's latest investor update puts regulatory progress for its Huntington's disease therapy at the center of the investment case. In a Nov. 4 release carried by Markets Insider, the company said the U.S. Food and Drug Administration had granted Priority Review to its biologics license application for ifezuntirgene inilparvovec, also known as AMT-130.

uniQure stock traded at 20.45 euros on Lang & Schwarz at 13:20 CET on Tuesday, November 10, 2026.

FDA Decision Remains Key Catalyst

The FDA set May 1, 2027 as the target action date under the Prescription Drug User Fee Act. The application uses the Accelerated Approval pathway and is supported by 36-month results from 12 high-dose patients compared with a propensity score-matched external control.

The company said 48-month follow-up showed a 44 percent slowing of progression on the composite Unified Huntington's Disease Rating Scale, although the result was not statistically significant. Total Functional Capacity showed a 61 percent slowing on a nominal statistical measure. A planned randomized confirmatory study is expected to enroll about 200 patients, with U.S. screening targeted by the end of 2026.

Revenue Growth With Narrower Loss

Revenue for the quarter ended Sept. 30 rose to 5.2 million US dollars from 3.7 million US dollars a year earlier, driven by higher license revenue. Net loss narrowed to 61.2 million US dollars, or 0.88 US dollars per share, from 80.5 million US dollars, or 1.38 US dollars per share.

Research and development expense increased to 35.5 million US dollars from 34.4 million US dollars, while selling, general and administrative expense rose to 23.9 million US dollars from 19.4 million US dollars. The higher costs reflect continued development and preparations for a possible commercial launch.

Cash Supports Pipeline Execution

Cash, cash equivalents and investment securities stood at 768.4 million US dollars on Sept. 30, compared with 622.5 million US dollars at the end of 2025. Management expects those resources to fund operations into 2030. The pipeline also includes AMT-260 for refractory mesial temporal lobe epilepsy and AMT-191 for Fabry disease, with updated results expected in the first half of 2027.

Broader market context is available in the Current market reports.

uniQure lists investor presentations and upcoming conference appearances on its More news and analyses on uniQure stock page.